Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics (NASDAQ: IPSC), a biotechnology company focused on developing iPSC-derived cell therapies, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Brent Pfeiffenberger will deliver a company presentation, which will be available via on-demand webcast starting September 5, 2025, at 7:00 a.m. ET.
The management team will also be available for investor meetings during the conference on September 9-10, 2025 in New York. Interested parties can access the presentation through Century's website, where it will remain available for at least 30 days.
Century Therapeutics (NASDAQ: IPSC), azienda biotecnologica specializzata nello sviluppo di terapie cellulari derivate da iPSC, ha annunciato la sua partecipazione al prossimo H.C. Wainwright 27th Annual Global Investment Conference. Il CEO Brent Pfeiffenberger terrà una presentazione aziendale, disponibile in webcast on-demand a partire dal 5 settembre 2025 alle 7:00 ET.
Il team dirigenziale sarà inoltre disponibile per incontri con investitori durante la conferenza il 9-10 settembre 2025 a New York. Chi fosse interessato può accedere alla presentazione tramite il sito di Century, dove resterà disponibile per almeno 30 giorni.
Century Therapeutics (NASDAQ: IPSC), compañía biotecnológica centrada en el desarrollo de terapias celulares derivadas de iPSC, anunció su participación en la próxima H.C. Wainwright 27th Annual Global Investment Conference. El director ejecutivo Brent Pfeiffenberger ofrecerá una presentación de la empresa, que estará disponible en webcast bajo demanda a partir del 5 de septiembre de 2025 a las 7:00 a.m. ET.
El equipo directivo también atenderá reuniones con inversores durante la conferencia el 9 y 10 de septiembre de 2025 en Nueva York. Los interesados pueden acceder a la presentación a través del sitio web de Century, donde permanecerá disponible al menos 30 días.
Century Therapeutics (NASDAQ: IPSC), iPSC 유래 세포 치료제 개발에 주력하는 생명공학 회사가 다가오는 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. CEO Brent Pfeiffenberger가 회사 프레젠테이션을 진행하며, 해당 발표는 2025년 9월 5일 오전 7시(동부시간)부터 온디맨드 웨비캐스트로 시청할 수 있습니다.
경영진은 또한 2025년 9월 9–10일 뉴욕에서 열리는 컨퍼런스 기간 동안 투자자 미팅을 진행할 예정입니다. 관심 있는 분들은 Century 웹사이트를 통해 프레젠테이션에 접속할 수 있으며 최소 30일간 게재될 예정입니다.
Century Therapeutics (NASDAQ: IPSC), une entreprise de biotechnologie spécialisée dans le développement de thérapies cellulaires dérivées d'iPSC, a annoncé sa participation à la prochaine H.C. Wainwright 27th Annual Global Investment Conference. Le PDG Brent Pfeiffenberger présentera l'entreprise ; la présentation sera disponible en webcast à la demande à partir du 5 septembre 2025 à 7h00 ET.
L'équipe de direction sera également disponible pour des réunions avec des investisseurs pendant la conférence, les 9 et 10 septembre 2025 à New York. Les personnes intéressées peuvent accéder à la présentation via le site de Century, où elle restera disponible pendant au moins 30 jours.
Century Therapeutics (NASDAQ: IPSC), ein Biotechnologieunternehmen, das sich auf die Entwicklung iPSC-abgeleiteter Zelltherapien spezialisiert hat, gab seine Teilnahme an der bevorstehenden H.C. Wainwright 27th Annual Global Investment Conference bekannt. CEO Brent Pfeiffenberger wird eine Unternehmenspräsentation halten, die ab dem 5. September 2025 um 7:00 Uhr ET als On-Demand-Webcast verfügbar sein wird.
Das Managementteam steht während der Konferenz am 9.–10. September 2025 in New York zudem für Investorenmeetings zur Verfügung. Interessierte können die Präsentation über die Century-Website abrufen, wo sie mindestens 30 Tage lang bereitgestellt wird.
- None.
- None.
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for meetings with investors at the conference from September 9-10, 2025, in New York, NY.
The on-demand webcast of the company presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025, on the Investors page of Century’s website at www.centurytx.com. The webcast will be archived on the company’s website for at least 30 days.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company leveraging its expertise in cellular reprogramming, genetic engineering, and manufacturing to develop cell therapies with the potential to provide meaningful advantages over existing cell therapies. Century’s genetically engineered, iPSC-derived cell therapy pipeline includes programs designed to address autoimmune diseases and cancers. Century believes its commitment to developing off-the-shelf cell therapies will expand patient access and provide an opportunity to advance the course of autoimmune disease and cancer care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
For More Information:
Century Therapeutics
Douglas Carr
Senior Vice President, Finance
investor.relations@centurytx.com
JPA Health
Sarah McCabe
smccabe@jpa.com
FAQ
When is Century Therapeutics (IPSC) presenting at the H.C. Wainwright Conference?
How can investors access Century Therapeutics' (IPSC) H.C. Wainwright conference presentation?
Will Century Therapeutics (IPSC) management be available for meetings during the conference?
What type of cell therapies is Century Therapeutics (IPSC) developing?
